Cargando…
Can HCQ Be Considered a “Safe Weapon” for COVID-19 in the Indian Population?
With no drugs currently approved for treatment and cure of COVID-19 (coronavirus disease 2019), hydroxychloroquine is one of the many first-line drugs used in the management. However, given the life-threatening adverse effects of HCQ that have been reported, its use as a prophylactic treatment remai...
Autores principales: | Thangaraju, Pugazhenthan, Venkatesan, Nanditha, Venkatesan, Sajitha, Gurunthalingam, Meenalotchini Prakash, Thangaraju, Eswaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351559/ https://www.ncbi.nlm.nih.gov/pubmed/32838163 http://dx.doi.org/10.1007/s42399-020-00392-z |
Ejemplares similares
-
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
COVID-19: Wait for a novel drug or act with the age old drug – Do we have a choice?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
COVID-19: Older drugs for a novel disease—Chloroquine, hydroxychloroquine, and possible Pentoxifylline—set to start the second innings?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020)